Bioactive eutectic systems for antimicrobial applications
This innovative solution leverages deep eutectic solvents (DES) based on saturated fatty acids to combat antimicrobial resistance. It demonstrates potent activity against Gram-positive bacteria and C. albicans, with potential for biofilm removal.
Overview
The bioactive eutectic systems developed by NOVA School of Science and Technology utilize deep eutectic solvents (DES) to create novel antimicrobial agents. These systems harness the synergistic effects of saturated fatty acids, showing significant antimicrobial activity. The CA:LA system, in particular, exhibits potent inhibitory and bactericidal effects against Gram-positive bacteria and C. albicans. This innovative approach addresses the growing challenge of antimicrobial resistance by providing an effective solution for biofilm removal without additional physical force.
Technical specifications
Key features:
- Deep Eutectic Solvents (DES): Formulated using saturated fatty acids to enhance synergistic antimicrobial properties.
- Antimicrobial Efficacy: Demonstrates significant activity against Gram-positive bacteria, C. albicans, and E. coli, specifically targeting biofilm formations.
- Biofilm Detachment: Effectively removes biofilms from tested microorganisms without the need for mechanical disruption.
Technology readiness level
This technology is currently at TRL 3, indicating experimental proof of concept. Further in vitro and in vivo testing is planned to validate its efficacy and understand the mechanisms involved in biofilm removal.
About Universidade NOVA de Lisboa
NOVA University Lisbon is a comprehensive public research institution spanning multiple campuses across the Lisbon metro area, combining selective excellence with an applied, collaborative ethos. Industry engages through co‑located laboratories at FCT NOVA and a science and technology park adjacent to the Caparica campus, alongside structured corporate partnership programs. Clinical translation is enabled by NOVA Medical School’s integration with Lisbon’s hospital network and clinical academic consortia, providing access to patient populations and real‑world settings. Research is supported by competitive European and Portuguese national funding, including Horizon Europe and the Foundation for Science and Technology, complemented by industry‑sponsored work. University‑wide innovation offices and school‑level TTOs provide IP, licensing, and startup support as a clear entry point for corporate R&D.
delivered to your inbox.